7AEG

SARS-CoV-2 main protease in a covalent complex with SDZ 224015 derivative, compound 5

7AEG の概要

• エントリーDOI: 10.2210/pdb7aeg/pdb
• 関連するBIRD辞書のPRD_ID: PRD_000338
• 分子名称: 3C-like proteinase, N-[(benzyloxy)carbonyl]-L-valyl-N-[(1S)-1-(carboxymethyl)-3-fluoro-2-oxopropyl]-L-alaninamide, DIMETHYL SULFOXIDE, ... (4 entities in total)
• 機能のキーワード: covid-19, inhibitor, protease, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 34559.99

構造登録者

Owen, C.D.,Redhead, M.A.,Lukacik, P.,Strain-Damerell, C.,Fearon, D.,Brewitz, L.,Collette, A.,Robinson, C.,Collins, P.,Radoux, C.,Navratilova, I.,Douangamath, A.,von Delft, F.,Malla, T.R.,Nugen, T.,Hull, H.,Tumber, A.,Schofield, C.J.,Hallet, D.,Stuart, D.I.,Hopkins, A.L.,Walsh, M.A. (登録日: 2020-09-17, 公開日: 2021-07-07, 最終更新日: 2024-10-23)

主引用文献

Redhead, M.A.,Owen, C.D.,Brewitz, L.,Collette, A.H.,Lukacik, P.,Strain-Damerell, C.,Robinson, S.W.,Collins, P.M.,Schafer, P.,Swindells, M.,Radoux, C.J.,Hopkins, I.N.,Fearon, D.,Douangamath, A.,von Delft, F.,Malla, T.R.,Vangeel, L.,Vercruysse, T.,Thibaut, J.,Leyssen, P.,Nguyen, T.T.,Hull, M.,Tumber, A.,Hallett, D.J.,Schofield, C.J.,Stuart, D.I.,Hopkins, A.L.,Walsh, M.A.
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.
Sci Rep, 11:13208-13208, 2021

PubMed Abstract: Effective agents to treat coronavirus infection are urgently required, not only to treat COVID-19, but to prepare for future outbreaks. Repurposed anti-virals such as remdesivir and human anti-inflammatories such as barcitinib have received emergency approval but their overall benefits remain unclear. Vaccines are the most promising prospect for COVID-19, but will need to be redeveloped for any future coronavirus outbreak. Protecting against future outbreaks requires the identification of targets that are conserved between coronavirus strains and amenable to drug discovery. Two such targets are the main protease (M) and the papain-like protease (PL) which are essential for the coronavirus replication cycle. We describe the discovery of two non-antiviral therapeutic agents, the caspase-1 inhibitor SDZ 224015 and Tarloxotinib that target M and PL, respectively. These were identified through extensive experimental screens of the drug repurposing ReFRAME library of 12,000 therapeutic agents. The caspase-1 inhibitor SDZ 224015, was found to be a potent irreversible inhibitor of M (IC 30 nM) while Tarloxotinib, a clinical stage epidermal growth factor receptor inhibitor, is a sub micromolar inhibitor of PL (IC 300 nM, K 200 nM) and is the first reported PL inhibitor with drug-like properties. SDZ 224015 and Tarloxotinib have both undergone safety evaluation in humans and hence are candidates for COVID-19 clinical evaluation.

PubMed: 34168183
DOI: 10.1038/s41598-021-92416-4

実験手法

X-RAY DIFFRACTION (1.7 Å)